London
Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Market Insights
Over 170 RNAi therapeutics are currently under development
Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.
RNAi therapeutics market is anticipated to increase at a CAGR of over 45% between 2019-2030
This growth is anticipated to be primarily driven by the target specificity of the drug candidates. North America (primarily the US) are expected to capture the majority share by 2030.
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/278/request-sample.html
The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry. The report includes detailed transcripts of discussions held with the following expert(s):
§ Amotz Shemi (Chief Executive Officer, Silenseed)
The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic area, indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).
§ Quark Pharmaceuticals
§ Alnylam Pharmaceuticals
§ Dicerna Pharmaceuticals
§ Souzhou Ribo Life Sciences
§ Olix Pharmaceuticals
§ Sirnaomics
§ Ariz Precision Medicine
§ Arrowhead Pharmaceuticals
§ Gradalis
§ Benitec Biopharma
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html or email [email protected]
You may also be interested in the following titles:
1. Gene Therapy Market (3rd Edition), 2019-2030
2. Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030
3. Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs Roots Analysis is pleased to announce the publication of its recent study, titled, “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030.” The report features an extensive study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications.
The study includes in-depth analyses, highlighting the capabilities of service providers engaged in this domain.
In addition to other elements, it includes:A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications.A competitiveness analysis of prominent oligonucleotide manufacturers, featuring insightful pictorial summaries and representations.Elaborate profiles of key players that offer a diverse range of capabilities for custom synthesis, modification and purification of oligonucleotides.An analysis of the various partnerships pertaining to oligonucleotide manufacturing, which have been established in the recent past.An analysis of the various expansion initiatives undertaken by service providers engaged in this domain.A detailed analysis of completed, ongoing and planned clinical research studies of various oligonucleotide-based drug products.An estimate of the overall, annual capacity for manufacturing oligonucleotides based on data reported by industry stakeholders in the public domain.An informed estimate of the annual clinical and commercial demand for oligonucleotides.A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing custom synthesis, modification and purification services for oligonucleotides.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) To request for customize report – https://www.rootsanalysis.com/reports/304/request-customization.html Type of ManufacturingCustom ManufacturingLarge-scale ManufacturingType of Oligonucleotides ManufacturedAntisense OligonucleotidesmiRNAsshRNAssiRNAsOther OligonucleotidesScale of OperationClinicalCommercialPurpose of ProductionIn-houseOutsourcedTarget Therapeutic AreaAutoimmune DisordersCardiovascular DisordersGenetic DisordersInfectious DiseasesMetabolic DisordersNeuromuscular DisordersOncological DisordersOphthalmic DisordersOther Therapeutic AreasSize of manufacturerSmallMid-sizedLargeKey Geographical Region North AmericaEuropeAsia-Pacific and Rest of the WorldTo request for sample report – https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/request-sample.html Transcripts of interviews held with the following senior level representatives of stakeholder companiesJoachim Bertram (Chief Scientific Officer and Managing Director, IBA Lifesciences)Tobias Pohlmann (Founder and Managing Director, BianoScience) Key companies covered in the reportAgilent TechnologiesAjinomoto Bio-Pharma ServicesBioSpringCordenPharmaIntegrated DNA TechnologiesKaneka EurogentecLGC Biosearch TechnologiesMicrosynthNitto Denko AveciaSigma AldrichThermo Fisher ScientificTrilink Biotechnologies For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html Other Recent OfferingsChina Biopharmaceutical Contract Manufacturing Market, 2020-2030Pharmaceutical Continuous Manufacturing Market, 2020-2030Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] - https://www.facebook.com/RootsAnalysisLinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/Twitter - https://twitter.com/RootsAnalysis
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
